Angiogenesis

Angiogenesis. It is the physiological process through which new blood vessels form from pre-existing vessels, a critical mechanism in development, wound healing, and the female reproductive cycle. This tightly regulated cascade is orchestrated by a balance of pro-angiogenic and anti-angiogenic signaling molecules, with vascular endothelial growth factor (VEGF) being a principal stimulator. Dysregulation of angiogenesis is a hallmark of numerous diseases, most notably cancer, making it a major target for therapeutic intervention.

Overview

Angiogenesis is distinct from vasculogenesis, which involves the *de novo* formation of vessels from angioblasts or endothelial progenitor cells. The process typically begins with the activation of endothelial cells in a pre-existing venule or capillary in response to signals like hypoxia. Key steps include enzymatic degradation of the surrounding basement membrane, endothelial cell migration and proliferation, and finally tube formation and stabilization through pericyte recruitment. This complex sequence is essential for supplying oxygen and nutrients during events like embryogenesis and the growth of the corpus luteum.

Regulation

The "angiogenic switch" is controlled by a precise equilibrium of stimulatory and inhibitory factors. Major pro-angiogenic signals include the VEGF family, fibroblast growth factors (FGFs), and angiopoietin-1, which bind to receptors like VEGFR-2 on endothelial cells. Naturally occurring inhibitors include thrombospondin-1, angiostatin (a fragment of plasminogen), and endostatin (derived from collagen XVIII). The hypoxia-inducible factor (HIF) pathway is a master regulator, upregulated in low-oxygen conditions to transcribe genes for VEGF and other factors. The extracellular matrix and interactions with pericytes also provide crucial contextual signals.

Role in disease

Pathological angiogenesis is a central feature of many conditions. In oncogenesis, tumors secrete VEGF to induce a dedicated blood supply, facilitating growth beyond 1-2 mm³ and enabling metastasis to distant sites like the liver or lungs. This "tumor angiogenesis" concept was pioneered by Judah Folkman. Excessive angiogenesis also drives diabetic retinopathy, age-related macular degeneration (AMD), psoriasis, and rheumatoid arthritis. Conversely, insufficient angiogenesis contributes to ischemic heart disease, stroke, and chronic wounds, where tissue repair is impaired.

Therapeutic applications

Therapeutic strategies aim to either inhibit or promote angiogenesis. Anti-angiogenic therapy, primarily for cancer, includes monoclonal antibodies like bevacizumab (targeting VEGF) and small-molecule tyrosine kinase inhibitors such as sunitinib and pazopanib. In ophthalmology, drugs like ranibizumab and aflibercept are used to treat neovascular AMD and diabetic macular edema. Pro-angiogenic approaches, termed "therapeutic angiogenesis," seek to stimulate vessel growth in ischemic tissues using gene therapy delivering VEGF or FGF, or cell therapy with bone marrow-derived mononuclear cells, though clinical success has been limited.

Measurement and research

Research utilizes diverse *in vitro*, *in vivo*, and clinical methods. Common assays include the chorioallantoic membrane (CAM) assay, the Matrigel plug assay in mouse models, and tube formation assays using human umbilical vein endothelial cells (HUVECs). Advanced imaging techniques like intravital microscopy and contrast-enhanced ultrasound allow dynamic visualization. Clinical assessment often involves measuring circulating biomarkers like VEGF or using dynamic contrast-enhanced MRI to quantify tumor vascular permeability. Major research institutions like the National Cancer Institute and organizations like the American Association for Cancer Research continue to drive the field forward.

Category:Physiological processes Category:Cell biology Category:Oncology